BRPI0918419A2 - nova formulação anticorpo - Google Patents
nova formulação anticorpoInfo
- Publication number
- BRPI0918419A2 BRPI0918419A2 BRPI0918419A BRPI0918419A BRPI0918419A2 BR PI0918419 A2 BRPI0918419 A2 BR PI0918419A2 BR PI0918419 A BRPI0918419 A BR PI0918419A BR PI0918419 A BRPI0918419 A BR PI0918419A BR PI0918419 A2 BRPI0918419 A2 BR PI0918419A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody formulation
- new antibody
- new
- formulation
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164746 | 2008-09-19 | ||
| PCT/EP2009/061692 WO2010031720A2 (en) | 2008-09-19 | 2009-09-09 | Novel antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0918419A2 true BRPI0918419A2 (pt) | 2015-11-24 |
Family
ID=41231968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0918419A BRPI0918419A2 (pt) | 2008-09-19 | 2009-09-09 | nova formulação anticorpo |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20100074903A1 (pt) |
| EP (1) | EP2328559B1 (pt) |
| JP (2) | JP5524967B2 (pt) |
| KR (2) | KR20140019035A (pt) |
| CN (1) | CN102159194A (pt) |
| AU (1) | AU2009294680A1 (pt) |
| BR (1) | BRPI0918419A2 (pt) |
| CA (1) | CA2736198A1 (pt) |
| CL (1) | CL2011000561A1 (pt) |
| ES (1) | ES2531385T3 (pt) |
| IL (1) | IL211190A0 (pt) |
| MX (1) | MX2011002402A (pt) |
| PE (1) | PE20110302A1 (pt) |
| SG (1) | SG2014011365A (pt) |
| WO (1) | WO2010031720A2 (pt) |
| ZA (1) | ZA201101343B (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07110370B2 (ja) | 1986-08-13 | 1995-11-29 | 昭和アルミニウム株式会社 | 温度制御自在な押出機のコンテナ |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| RU2012139181A (ru) | 2010-02-26 | 2014-04-10 | Ново Нордиск А/С | Стабильная композиция, содержащая антитело |
| MX2012013586A (es) | 2010-05-28 | 2013-01-24 | Novo Nordisk As | Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante. |
| NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| KR20220136466A (ko) | 2011-01-28 | 2022-10-07 | 사노피 바이오테크놀로지 | 특정 대상자 그룹의 치료 방법에 이용하기 위한 pcsk9에 대한 인간 항체 |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EP2771029A4 (en) | 2011-10-25 | 2015-07-01 | Onclave Therapeutics Ltd | ANTIBODY FORMULATIONS AND METHOD THEREFOR |
| AR090244A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Formulacion de anticuerpo anti-selectina p |
| EP2968538A1 (en) | 2013-03-15 | 2016-01-20 | Bayer HealthCare LLC | Anti-prolactin receptor antibody formulations |
| BR112016008576B1 (pt) | 2013-10-24 | 2023-03-07 | Astrazeneca Ab | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2017031151A1 (en) | 2015-08-18 | 2017-02-23 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| JP2018535242A (ja) * | 2015-11-30 | 2018-11-29 | メディミューン,エルエルシー | 高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN110167531B (zh) | 2017-01-11 | 2025-06-03 | 赛特瑞恩股份有限公司 | 稳定的液体调配物 |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| WO2022187834A1 (en) * | 2021-03-03 | 2022-09-09 | Allakos Inc. | Anti-siglec-8 antibody formulations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800815A (en) * | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
| US4783399A (en) | 1984-05-04 | 1988-11-08 | Scripps Clinic And Research Foundation | Diagnostic system for the detection of cytomegalovirus |
| JPH07502726A (ja) | 1991-09-30 | 1995-03-23 | バイオゲン インコーポレイテッド | 抗−padgem抗体を用いる血管狭窄の抑制 |
| NZ252542A (en) | 1992-05-05 | 1997-08-22 | Cytel Corp | Compositions of blocking p-selectin antibodies and their use in treating inflammatory or thrombotic disease |
| CA2292730C (en) * | 1997-06-13 | 2008-09-16 | Genentech, Inc. | Stabilized antibody formulation |
| ES2392073T3 (es) | 2001-11-08 | 2012-12-04 | Abbott Biotherapeutics Corp. | Formulación farmacéutica líquida estable de anticuerpos IGG |
| US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP2357201B1 (en) * | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| ES2707284T3 (es) * | 2005-03-08 | 2019-04-03 | Pfizer Prod Inc | Composiciones de anticuerpo anti-CTLA-4 |
| CA2638811A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| CL2007003583A1 (es) * | 2006-12-11 | 2008-07-18 | Hoffmann La Roche | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. |
-
2009
- 2009-09-09 MX MX2011002402A patent/MX2011002402A/es active IP Right Grant
- 2009-09-09 ES ES09782818T patent/ES2531385T3/es active Active
- 2009-09-09 WO PCT/EP2009/061692 patent/WO2010031720A2/en not_active Ceased
- 2009-09-09 KR KR1020147001758A patent/KR20140019035A/ko not_active Abandoned
- 2009-09-09 PE PE2011000614A patent/PE20110302A1/es not_active Application Discontinuation
- 2009-09-09 CA CA2736198A patent/CA2736198A1/en not_active Abandoned
- 2009-09-09 KR KR1020117006209A patent/KR20110047232A/ko not_active Ceased
- 2009-09-09 AU AU2009294680A patent/AU2009294680A1/en not_active Abandoned
- 2009-09-09 SG SG2014011365A patent/SG2014011365A/en unknown
- 2009-09-09 BR BRPI0918419A patent/BRPI0918419A2/pt not_active IP Right Cessation
- 2009-09-09 EP EP09782818.0A patent/EP2328559B1/en not_active Not-in-force
- 2009-09-09 JP JP2011527294A patent/JP5524967B2/ja not_active Expired - Fee Related
- 2009-09-09 CN CN2009801368376A patent/CN102159194A/zh active Pending
- 2009-09-15 US US12/559,555 patent/US20100074903A1/en not_active Abandoned
-
2011
- 2011-02-10 IL IL211190A patent/IL211190A0/en not_active IP Right Cessation
- 2011-02-18 ZA ZA2011/01343A patent/ZA201101343B/en unknown
- 2011-03-17 CL CL2011000561A patent/CL2011000561A1/es unknown
-
2012
- 2012-07-30 US US13/561,233 patent/US20120321638A1/en not_active Abandoned
-
2013
- 2013-04-01 US US13/854,254 patent/US20130209478A1/en not_active Abandoned
- 2013-09-19 US US14/031,199 patent/US20140093512A1/en not_active Abandoned
-
2014
- 2014-01-17 JP JP2014006650A patent/JP2014094958A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20140093512A1 (en) | 2014-04-03 |
| JP5524967B2 (ja) | 2014-06-18 |
| US20130209478A1 (en) | 2013-08-15 |
| EP2328559A2 (en) | 2011-06-08 |
| US20120321638A1 (en) | 2012-12-20 |
| MX2011002402A (es) | 2011-04-05 |
| WO2010031720A3 (en) | 2010-09-23 |
| ES2531385T3 (es) | 2015-03-13 |
| AU2009294680A1 (en) | 2010-03-25 |
| KR20110047232A (ko) | 2011-05-06 |
| SG2014011365A (en) | 2014-05-29 |
| CA2736198A1 (en) | 2010-03-25 |
| CN102159194A (zh) | 2011-08-17 |
| KR20140019035A (ko) | 2014-02-13 |
| PE20110302A1 (es) | 2011-05-21 |
| US20100074903A1 (en) | 2010-03-25 |
| JP2012502942A (ja) | 2012-02-02 |
| JP2014094958A (ja) | 2014-05-22 |
| EP2328559B1 (en) | 2015-01-07 |
| WO2010031720A2 (en) | 2010-03-25 |
| IL211190A0 (en) | 2011-04-28 |
| ZA201101343B (en) | 2011-11-30 |
| CL2011000561A1 (es) | 2011-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0918419A2 (pt) | nova formulação anticorpo | |
| DK3072906T3 (da) | Antistofformulering | |
| EP2358392A4 (en) | ANTIBODY FORMULATION | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| DK2234600T3 (da) | Antistofformulering | |
| IL212175B (en) | Muc1* antibodies | |
| BRPI1006519A2 (pt) | formulação de anticorpos | |
| BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
| EP2248470A4 (en) | APPLICATOR | |
| EP2337798A4 (en) | SPECIFIC ANTIBODIES OF THE ASB | |
| PT2813570T (pt) | Resumo | |
| BRPI0906749A2 (pt) | Composição | |
| BRPI0913808A2 (pt) | composição | |
| PT3045471T (pt) | Resumo | |
| DK2252395T3 (da) | Afsvovlingsmaterialer | |
| BRPI0917231A2 (pt) | composição | |
| BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
| EP2284538A4 (en) | Biosensor | |
| EP2280284A4 (en) | Biosensor | |
| BRPI0914098A2 (pt) | biosensor | |
| BRPI0912769A2 (pt) | anticorpos anti-pirb | |
| EP2357204A4 (en) | COMPOSITION | |
| DK2382224T3 (da) | Metalhydracid-materialer | |
| DK2254963T3 (da) | Kerne-skal-flowforbedrer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |